Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)

被引：1
|
作者：
Rubinsak, J. R.
Spigel, D. R.
Hainsworth, J. D.
Webb, C.
Inhorn, R. C.
Infante, J. R.
Yardley, D. A.
Burris, H. A., III
Vazquez, E. R.
Greco, F. A.
机构：
[1] Florida Canc Specialists, Ft Myers, FL USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Tennessee Oncol, Nashville, TN USA
[4] Mercy Hosp, Portland, ME USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.19045
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19045
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
    Georgoulias, V
    Kouroussis, C
    Androulakis, N
    Kakolyris, S
    Dimopoulos, MA
    Papadakis, E
    Bouros, D
    Apostolopoulou, F
    Papadimitriou, C
    Agelidou, A
    Hatzakis, K
    Kalbakis, K
    Kotsakis, A
    Vardakis, N
    Vlachonicolis, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 914 - 920
  • [12] Vinorelbine/gemcitabine in advanced non-small-cell lung cancer: an AASLC phase II trial
    Krajnik, G
    Malayeri, R
    Thaler, J
    Mohn-Staudner, A
    Greil, R
    Schmeikal, S
    Marhold, F
    Deutsch, J
    Preiss, P
    Zoechbauer-Mueller, S
    Huber, H
    Pirker, R
    [J]. 17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 647 - 649
  • [13] A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC)
    Wells, Leah
    Qin, Angel
    Rice, John
    Gadgeel, Shirish M.
    Schneider, Bryan J.
    Ramnath, Nithya
    Zhao, Lili
    Kalemkerian, Gregory Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [14] Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study
    Pectasides, D
    Aspropotamitis, A
    Halikia, A
    Visvikis, A
    Antoniou, F
    Kalantaridou, A
    Karvounis, N
    Batzios, S
    Athanassiou, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3816 - 3821
  • [15] Phase II study of docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Takigawa, N
    Segawa, Y
    Kishino, D
    Fujiwara, K
    Shinkai, T
    Watanabe, Y
    Tabata, M
    Kiura, K
    Ueoka, H
    Tanimoto, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 776S - 776S
  • [16] Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: A phase II trial of sequential chemotherapy
    Dols M.C.
    Chamorro E.V.
    Díaz I.A.
    Calle S.G.
    García J.A.
    Calderón V.G.
    Ocón F.C.
    Pino Á.M.
    Bretón García J.J.
    Orgaz M.B.
    [J]. Clinical and Translational Oncology, 2006, 8 (10) : 742 - 749
  • [17] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [18] Multicenter phase H trial of biweekly carboplatin and gemcitabine for untreated advanced non-small-cell lung cancer (NSCLC)
    Dómine, M
    Gómez, RG
    Firvida, JL
    Delgado, JR
    Estévez, LG
    León, A
    Casado, V
    Alvarez, R
    Alfonso, AL
    Lobo, F
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 308 - 308
  • [19] Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
    Zalcberg, J
    Millward, M
    Bishop, J
    McKeage, M
    Zimet, A
    Toner, G
    Friedlander, M
    Barter, C
    Rischin, D
    Loret, C
    James, R
    Bougon, N
    Berille, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1948 - 1953
  • [20] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345